#USA #Carlsbad #Pictor Holdings #Targeted Proteomics #Proteomic Platform

Pictor Holdings Inc. Secures $7.5 Million Investment

Pictor Holdings Inc., a leading company in the field of targeted proteomics, has announced it has successfully closed a $7.5 million bridge financing round. This funding round comes from pre-existing investors and aims to propel the commercial expansion of the company’s innovative proteomic platform. Based in Carlsbad, California, Pictor focuses on developing advanced solutions for both human and animal health markets.

With this latest investment, Pictor has now raised around $30 million in total capital, allowing the company to further its partnerships and enhance the scale of its platform's development and manufacturing processes. The funding will also facilitate extensive translational studies that are vital for significant advancements in proteomics.

The Pictor platform features the PictArray®, PictImager®, and Pictorial® software, which collectively allow laboratories to analyze up to 20 protein targets from a single sample in less than two hours. This cutting-edge technology is designed to simplify workflows and reduce both costs and complexity, offering significant advantages in pharmaceutical applications, reference laboratories, and animal health sectors.

Dr. Jamie Platt, CEO and co-founder of Pictor Holdings, emphasized the importance of making proteomic assays accessible beyond traditionally specialized contexts. He stated, “Pictor's platform is designed to make protein insights more accessible, practical, and economical.” The aim is to improve health outcomes across human and animal populations efficiently.

In its inaugural year at the U.S. headquarters, Pictor has achieved notable milestones, including the launch of seven commercial products and the establishment of four strategic partnerships. The company has also made key appointments, welcoming industry veterans Terry Kelly, PhD, as Chief Operating Officer and Tim Shannon as Chief Financial Officer, to strengthen its leadership team.

The proceeds from the bridge round will support ongoing development efforts, as Pictor seeks to expand its network of partners while advancing large-scale studies in priority sectors. The company anticipates entering stages of licensing with multiple partners within the upcoming 12 to 18 months. Furthermore, it is assessing the potential for a Series A financing round to continue its growth trajectory.

Shannon noted the encouraging response from existing investors, asserting their confidence in the company’s operational model. He mentioned, “This capital positions Pictor to accelerate partnerships and scale operations as we advance toward our Series A.”

As Pictor expands its commercial operations, its innovative approaches promise to reshape the landscape of proteomics, opening up new avenues in health diagnostics and treatment methodologies.

Pictor Holdings Inc. operates not only in the United States but also has laboratory and commercial operations in New Zealand, Australia, and India. This global presence underscores its commitment to advancing multi-analyte proteomic solutions that enable laboratories to conduct numerous tests more rapidly and cost-effectively, ultimately benefiting the healthcare field significantly.

For more information regarding Pictor Holdings, visit www.pictorproteomics.com.